Suppr超能文献

严重急性呼吸综合征冠状病毒2感染的恒河猴亚基因组RNA与总RNA的比较

Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques.

作者信息

Dagotto Gabriel, Mercado Noe B, Martinez David R, Hou Yixuan J, Nkolola Joseph P, Carnahan Robert H, Crowe James E, Baric Ralph S, Barouch Dan H

机构信息

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Harvard Medical School, Boston, MA 02115, USA.

出版信息

J Virol. 2021 Mar 25;95(8). doi: 10.1128/JVI.02370-20. Epub 2021 Jan 20.

Abstract

Respiratory virus challenge studies involve administration of the challenge virus and sampling to assess for protection from the same anatomical locations. It can therefore be difficult to differentiate actively replicating virus from input challenge virus. For SARS-CoV-2, specific monitoring of actively replicating virus is critical to investigate the protective and therapeutic efficacy of vaccines, monoclonal antibodies, and antiviral drugs. We developed a SARS-CoV-2 subgenomic RNA (sgRNA) RT-PCR assay to differentiate productive infection from inactivated or neutralized virus. Subgenomic RNAs are generated after cell entry and are poorly incorporate into mature virions, and thus may provide a marker for actively replicating virus. We show envelope (E) sgRNA was degraded by RNase in infected cell lysates, while genomic RNA (gRNA) was protected, presumably due to packaging into virions. To investigate the capacity of the sgRNA assay to distinguish input challenge virus from actively replicating virus , we compared the E sgRNA assay to a standard nucleoprotein (N) or E total RNA assay in convalescent rhesus macaques and in antibody-treated rhesus macaques after experimental SARS-CoV-2 challenge. In both studies, the E sgRNA assay was negative, suggesting protective efficacy, whereas the N and E total RNA assays remained positive. These data suggest the potential utility of sgRNA to monitor actively replicating virus in prophylactic and therapeutic SARS-CoV-2 studies.Developing therapeutic and prophylactic countermeasures for the SARS-CoV-2 virus is a public health priority. During challenge studies, respiratory viruses are delivered and sampled from the same anatomical location. It is therefore important to distinguish actively replicating virus from input challenge virus. The most common assay for detecting SARS-CoV-2 virus, reverse transcription polymerase chain reaction (RT-PCR) targeting nucleocapsid total RNA, cannot distinguish neutralized input virus from replicating virus. In this study, we assess SARS-CoV-2 subgenomic RNA as a potential measure of replicating virus in rhesus macaques.

摘要

呼吸道病毒攻毒研究涉及施用攻毒病毒并进行采样,以评估相同解剖部位的保护情况。因此,很难区分正在活跃复制的病毒和输入的攻毒病毒。对于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)而言,特异性监测正在活跃复制的病毒对于研究疫苗、单克隆抗体和抗病毒药物的保护及治疗效果至关重要。我们开发了一种SARS-CoV-2亚基因组RNA(sgRNA)逆转录聚合酶链反应(RT-PCR)检测方法,以区分有生产性感染的病毒与灭活或中和的病毒。亚基因组RNA在病毒进入细胞后产生,很少掺入成熟病毒粒子中,因此可能为正在活跃复制的病毒提供一个标志物。我们发现,在感染细胞裂解物中,包膜(E)sgRNA被核糖核酸酶降解,而基因组RNA(gRNA)受到保护,推测这是由于其被包装进了病毒粒子。为了研究sgRNA检测方法区分输入攻毒病毒和正在活跃复制病毒的能力,我们在实验性SARS-CoV-2攻毒后的恢复期恒河猴和抗体处理的恒河猴中,将E sgRNA检测方法与标准核蛋白(N)或E总RNA检测方法进行了比较。在两项研究中,E sgRNA检测均为阴性,表明具有保护效果,而N和E总RNA检测仍为阳性。这些数据表明,sgRNA在SARS-CoV-2预防性和治疗性研究中监测正在活跃复制病毒方面具有潜在用途。为SARS-CoV-2病毒开发治疗和预防对策是公共卫生的优先事项。在攻毒研究中,呼吸道病毒从相同解剖部位递送和采样。因此,区分正在活跃复制的病毒和输入攻毒病毒很重要。检测SARS-CoV-2病毒最常用的方法,即针对核衣壳总RNA的逆转录聚合酶链反应(RT-PCR),无法区分中和的输入病毒和复制病毒。在本研究中,我们评估了SARS-CoV-2亚基因组RNA作为恒河猴中复制病毒潜在指标的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d2/8103707/58ce1a3f2dde/JVI.02370-20-f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验